Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case for blood pressure control in risk groups.

L M Ruilope1, M Volpe

  • 1Hospital 12 de Octubre, Servico di Nefrologia, Madrid, Spain.

International Journal of Clinical Practice
|November 9, 2004
PubMed
Summary

Hypertension often coexists with other cardiovascular disease risk factors. Combination therapy, such as angiotensin receptor blockers with diuretics, is effective for managing blood pressure and overall risk in high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Oral health, hypertension and cardiovascular diseases.

Hipertension y riesgo vascular·2023
Same author

Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration.

Hipertension y riesgo vascular·2022
Same author

[2022 Practice guidelines for the management of arterial hypertension of the Spanish Society of Hypertension].

Hipertension y riesgo vascular·2022
Same author

2021 Spanish Society of Hypertension position statement about telemedicine.

Hipertension y riesgo vascular·2021
Same author

[Awareness, treatment and control of blood pressure according to place of recruitment and sex in the May Measure Month 2018 survey in Spain].

Hipertension y riesgo vascular·2020

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension frequently presents with comorbid cardiovascular disease (CVD) risk factors.
  • Individualized CVD risk assessment is crucial for effective patient management.
  • Elevated blood pressure and CVD risk factors are interconnected, necessitating comprehensive treatment strategies.

Purpose of the Study:

  • To emphasize the importance of tailored treatment approaches for hypertensive patients.
  • To highlight the benefits of combination therapy in reducing overall cardiovascular risk.
  • To discuss the role of the Valsartan long-term evaluation (VALUE) trial in understanding combination treatment.

Main Methods:

  • Review of existing literature on hypertension and cardiovascular disease.
  • Analysis of risk factor profiles in hypertensive individuals.
  • Consideration of data from major clinical trials, including the VALUE trial.

Main Results:

  • Hypertension management requires addressing multiple cardiovascular risk factors.
  • Combination therapy, particularly with angiotensin receptor blockers and diuretics, offers a safe and effective approach.
  • The VALUE trial provides critical insights into combination treatment for high-risk populations.

Conclusions:

  • Individualized risk assessment and tailored treatment are paramount in hypertension management.
  • Combination therapy is essential for effectively lowering both blood pressure and overall cardiovascular risk.
  • Further research and clinical trials like VALUE are vital for optimizing hypertension treatment strategies.

Related Experiment Videos